Skip to main content
SM

Super Melanin

Super Melanin offers a patented biomimetic technology platform that accelerates skin and tissue regeneration by integrating advances in chemistry, materials science, biology, and medicine. The solution targets unmet clinical needs in regenerative care, applying a decade of research to create treatments that enhance natural repair processes. It is positioned for use in medical and aesthetic applications requiring improved healing outcomes.

Chicago, IllinoisFounded 20234100+ followers
Updated 1 month ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Current skin and tissue repair treatments often result in slow healing, incomplete regeneration, and limited effectiveness for chronic wounds, leading to prolonged patient discomfort and higher healthcare costs.

Solution

Super Melanin provides a patented biomimetic technology platform that uses synthetic melanin analogs to actively modulate cellular signaling pathways involved in tissue regeneration. By integrating principles from chemistry, materials science, biology, and medicine, the platform accelerates wound closure and promotes more complete tissue repair. The system is designed for clinical translation, targeting unmet needs in regenerative care and offering a science‑backed alternative to conventional therapies.

Target Audience

Primary customers are clinicians and healthcare providers specializing in wound care, dermatology, and reconstructive surgery, as well as medical device manufacturers seeking regenerative solutions.

Features

  • Biomimetic melanin analogs that interact with key cellular pathways to enhance proliferation and extracellular matrix formation
  • Proprietary formulation combining chemistry and materials science for controlled release and sustained activity at the wound site
  • Scalable platform adaptable to various skin and soft‑tissue applications, including chronic wounds and post‑surgical repair
  • Patented technology ensuring unique mechanism of action and intellectual property protection
  • Compatibility with existing clinical workflows, allowing integration as a topical or injectable adjunct to standard care
This profile is AI-generated and may contain inaccuracies.